Integra LifeSciences Holdings Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated May 5, 2026, reports the financial results for Integra LifeSciences Holdings Corporation for the quarter ended March 31, 2026. The filing incorporates by reference a press release (Exhibit 99.1) containing detailed financial data and reconciliations of GAAP to non-GAAP measures.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It confirms that the attached press release contains:
- Reconciliations of GAAP revenues to organic revenues.
- Reconciliations of GAAP net income to adjusted EBITDA and adjusted net income.
- Reconciliations of GAAP gross profit/margin to adjusted gross profit/margin.
- Reconciliations of GAAP earnings per diluted share to adjusted earnings per diluted share.
- Reconciliations of GAAP total debt to net debt.
- Reconciliations of GAAP operating cash flow to free cash flow and adjusted free cash flow conversion.
Material Changes and Adjustments
Management utilizes non-GAAP measures to exclude items that vary significantly in timing or magnitude. Key adjustments described include:
- Structural Optimization: Severance, facility exit costs, and infrastructure rationalization.
- M&A Activity: Acquisition, divestiture, and integration-related charges, including inventory fair value adjustments.
- Regulatory and Operational: EU Medical Device Regulation compliance costs and charges related to the Boston facility recall and transition to Braintree.
- Non-Cash Items: Intangible asset amortization and impairment charges (noted as related to tariff uncertainty and quality/supply issues).
- Currency: Organic revenue excludes the effects of foreign exchange rate fluctuations.
Guidance, Outlook, and Risks
The company provided forward-looking guidance for organic revenues and adjusted earnings per diluted share. However, it did not provide reconciliations to forward-looking GAAP measures due to the high variability of foreign exchange rates and certain GAAP expense items.
Risks and Contingencies:
- Foreign Exchange: Significant revenue generation outside the U.S. creates exposure to currency fluctuations.
- Regulatory Compliance: Ongoing costs associated with EU Medical Device Regulations.
- Operational Disruptions: Historical impact from the Boston facility recall and transition.
- Economic Uncertainty: Recent tariff changes have created broad economic uncertainty and contributed to goodwill impairment charges.
- M&A Execution: Future acquisitions may incur significant expenses or result in aborted deals.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific numerical values of Q1 2026 GAAP and non-GAAP results.
- Verify the magnitude of goodwill impairment charges and their specific drivers regarding tariffs and market capitalization.
- Assess the impact of foreign exchange rates on reported revenue versus organic growth.
- Confirm the status and cost implications of the transition from the Boston facility to the Braintree facility.
- Examine the reconciliation tables to understand the tax impact of non-GAAP adjustments.